We know that drug development is both an art and a science.

The work we do is incredibly technical, intentional, and specific, but there is an art to it - because we must leave room for creativity, innovation and spontaneity. Murals are paintings that transform overlooked or unused spaces - creating something impactful and meaningful. There remains many overlooked opportunities in cancer drug development. This is what inspires us.

Our mission is simple, to create novel immunotherapies that can change patients’ lives so they can get back to what matters most - living.

Mural Oncology is leveraging its industry-leading protein engineering platform to revolutionize cytokine-based immunotherapies for the treatment of cancer. 

Immunotherapies have been transformative for some people living with cancer, but unfortunately many patients still do not benefit - either because they are ineligible for treatment or they do not respond well to current therapies.  

We leverage our expertise in cytokine biology, immune cell modulation and our protein engineering capabilities to develop first and novel immunotherapies. Our goal is to deliver meaningful, clinical benefit across a wide range of cancers, including tumor types where immunotherapies have previously not been effective.

Mural Oncology is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers. (NASDAQ: MURA)


Mural Oncology

Today marks a notable milestone as Mural Oncology officially launches as an independent, publicly traded, clinical-stage immuno-oncology company. Tomorrow, find us on Nasdaq as $MURA.

Mural's dedication to advancing our pipeline of novel engineered cytokine immunotherapies with our lead candidate, nemvaleukin alfa, is backed by a strong foundation of $275 million in committed funding, and a clear vision to reimagine cytokine-based immunotherapies for the treatment of cancer. 

Our mission is simple: to create novel immunotherapies that can change patients’ lives so they can get back to what matters most - living. Learn more:  https://bit.ly/47AUnhN #oncology #biotechnology #innovation #immunooncology #Nasdaq

IPhone / Mobile Compatible

SSL by Default

Google Tag Manager

Apple Mobile Web Clips Icon

Google Font API

Google Analytics

HSTS

WordPress

LetsEncrypt

Director, Talent Acquisition & Human Resources

AnnMarie Blunda

Associate Director of Information Technology

Dawn Dionne-Hamlin

Associate Director R&D Quality

Donna DeHaven

Senior Director, External Operations & Supply Chain

James Oleary

Senior Director Protein Therapeutics

Jean Chamoun

Director of Operations, Medical Affairs

Kat Long

Senior Director, Head of IT Applications

Katie Lund

Director, Corporate Communications

Katie Sullivan

Sr. Director, R&D Quality

Lance Lang

Senior Director, Regulatory Operations

Michele Liguori

Caroline J Loew

Chief Executive Officer Designate

Companies That Exited in 2023 (Top 10K)

United States Companies (Top 10K)

Massachusetts Companies that Exited

Northeastern US Oncology Companies

Mural Oncology is an independent public company. Mural Oncology would focus on the discovery and development of cancer therapies, including the continued development of nemvaleukin alfa and the company's portfolio of novel, preclinical engineered cytokines, comprised of tumor-targeted split interleukin-12 (IL-12) and interleukin-18 (IL-18).

Alkermes

Corporate Round - Mural Oncology

Waltham

Massachusetts

United States

North America

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mural Oncology appoints Sachiyo Minegishi to board of directors

Mural Oncology to Present at Two Upcoming Investor Conferences

Mural Oncology appoints new independent director

Mural Oncology appoints George Golumbeski to board

Mural Oncology presents clinical data from Artistry-3 at ASCO

Philippines

Asia

India

Spain

Europe

Estonia

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

Mural Oncology plc Ordinary Shares

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Oct 30, 2024 1:02 PM	58dc987e
crunchbase profile	general	Oct 30, 2024 10:26 PM	41457936
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	feb2fe0f
peers	general
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

MURA

COM:MURALONCOLOGY

Mural Oncology plc

Last Close

3.37

22/11 21:00

Market Cap

57.15M

Beta: -

Volume Today

60.63K

Avg: -